BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 32109718)

  • 1. All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy.
    Lanitis E; Coukos G; Irving M
    Curr Opin Biotechnol; 2020 Oct; 65():75-87. PubMed ID: 32109718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
    Giordano Attianese GMP; Ash S; Irving M
    Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors.
    Chen J; Jiang H
    Crit Rev Immunol; 2021; 41(1):1-12. PubMed ID: 33822521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering.
    Zhang C; Zhuang Q; Liu J; Liu X
    ACS Synth Biol; 2022 Jan; 11(1):1-15. PubMed ID: 35005887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining chemotherapy with CAR-T cell therapy in treating solid tumors.
    Wang AX; Ong XJ; D'Souza C; Neeson PJ; Zhu JJ
    Front Immunol; 2023; 14():1140541. PubMed ID: 36949946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progression in chimeric antigen receptor T (CAR-T) cell therapy of solid tumors: A review].
    Fang Z; Han H; Liang L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Oct; 35(10):944-948. PubMed ID: 31814572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment.
    Antoñana-Vildosola A; Zanetti SR; Palazon A
    Int Rev Cell Mol Biol; 2022; 370():123-147. PubMed ID: 35798503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptors for the Tumour Microenvironment.
    Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
    Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene modification strategies for next-generation CAR T cells against solid cancers.
    Tian Y; Li Y; Shao Y; Zhang Y
    J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
    Qian L; Chen J; Wu X; Jing R; Sun J
    Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-T in solid tumors: Blazing a new trail through the brambles.
    Guo F; Cui J
    Life Sci; 2020 Nov; 260():118300. PubMed ID: 32827541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bright future or blind alley? CAR-T cell therapy for solid tumors.
    Zhang K; Chen H; Li F; Huang S; Chen F; Li Y
    Front Immunol; 2023; 14():1045024. PubMed ID: 36761757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects and challenges for use of CAR T cell therapies in solid tumors.
    Ramakrishna S; Barsan V; Mackall C
    Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
    [No Abstract]   [Full Text] [Related]  

  • 19. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
    Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V
    J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system.
    Wang X; Wu Z; Qiu W; Chen P; Xu X; Han W
    Front Med; 2020 Dec; 14(6):726-745. PubMed ID: 32794014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.